Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Urinary Bladder Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Pemetrexed 9Cisplatin 9pembrolizumab 5defactinib 3Cyclophosphamide 3sodium thiosulfate 2Radiotherapy, Intensity-Modulated 2Platinum 2Immunoenzyme Techniques 2Doxorubicin 21,2-diaminocyclohexaneplatinum II citrate 2vatalanib 1spartalizumab 1osimertinib 1nintedanib 1liposomal doxorubicin 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1amatuximab 1alvocidib 1aldesleukin 1X-Rays 1VS-5584 1Trabectedin 1Tetrahydrouridine 1Specimen Handling 1Ramucirumab 1Radiotherapy 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Mesothelioma, Malignant × Tetrahydrouridine × Clear all
NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡